APGE: SEC Form 15-12G filed by Apogee Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for APGE
Across the 21 sessions after earlier APGE headlines, the stock closed higher 11 times and lower 10 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | APGE | SPY |
|---|---|---|---|
| Aug 10, 2026 | Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | -0.1% | -0.0% |
| May 29, 2026 | Apogee Therapeutics to Participate in Upcoming June Conferences | +5.6% | +0.2% |
| May 27, 2026 | Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibartand 2 other headlines that session | -6.1% | -0.0% |
| May 11, 2026 | Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results | +1.9% | +0.2% |
| May 1, 2026 | Rothschild & Co Redburn initiated coverage on Apogee Therapeutics with a new price target | -2.6% | +0.3% |
| Mar 27, 2026 | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million | -0.8% | -1.7% |
Quantisnow market dataNASDAQ
APGE
Apogee Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2023
Get push alerts for APGE
Full APGE profile on Quantisnow Follow APGE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time